Seres Therapeutics outlines Phase II SER-155 trial plans as company extends cash runway through Q2 2026
Source: SeekingAlpha
2025-11-05 14:12:11 ET
More on Seres Therapeutics
- Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript
- Seres Therapeutics cuts 25% of workforce to extend cash runway into Q2 2026
- Biggest stock movers Monday: RAPP, MCRB, SATS, QS, SMMT and more
- Seeking Alpha’s Quant Rating on Seres Therapeutics
- Historical earnings data for Seres Therapeutics
Read the full article on Seeking Alpha
For further details see:
Seres Therapeutics outlines Phase II SER-155 trial plans as company extends cash runway through Q2 2026
Seres Therapeutics Inc.
NASDAQ: MCRB
MCRB Trading
0.54% G/L:
$9.23 Last:
9,048 Volume:
$9.32 Open:
MCRB Latest News
March 02, 2026 04:05:00 pm
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
February 12, 2026 07:00:00 am
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
January 06, 2026 07:00:00 am
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst(TM) Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
November 05, 2025 07:00:00 am
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
MCRB Stock Data
$129,727,082
7,418,146
0.38%
16
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
